Synthesis and functional evaluation of proteinogenic amino acid-derived synthetic cannabinoid receptor agonists related to MPP-5F-PICA, MMB-5F-PICA, and MDMB-5F-PICA.
Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Eric SparkesLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.ORCID https://orcid.org/0000-0001-7296-9804
Jack W MarkhamLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.ORCID https://orcid.org/0000-0003-4744-7662
Rochelle BoydLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.
Michael UdohLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.
Rebecca GordonLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.ORCID https://orcid.org/0009-0009-2040-6677
Humayra ZamanMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University Sydney NSW 2109 Australia.
Katelyn A WalkerLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.
Chianna DaneSchool of Chemistry, Faculty of Science, The University of Sydney NSW 2050 Australia.
Richard C KevinLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.ORCID https://orcid.org/0000-0002-4912-4499
Marina J SantiagoMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University Sydney NSW 2109 Australia.ORCID https://orcid.org/0000-0001-9388-8309
Samuel D BanisterLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.ORCID https://orcid.org/0000-0002-4690-4318
Adam AmetovskiLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.
Elizabeth A CairnsLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney 94 Mallett St, Building M02F, Camperdown Sydney NSW 2050 Australia elizabeth.cairns@sydney.edu.au.ORCID https://orcid.org/0000-0002-9816-4761
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Synthetic cannabinoid receptor agonists (SCRAs) comprise the second largest class of new psychoactive substances (NPS), and typically α-amino acid moieties are incorporated as part of their design. Limited investigation has been performed into elucidating structure-activity relationships around commonly used α-amino acid-derived head groups, mainly with valine and
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis and functional evaluation of proteinogenic amino acid-derived synthetic cannabinoid receptor agonists related to MPP-5F-PICA, MMB-5F-PICA, and MDMB-5F-PICA. · full record | OpenQuestion